Current research suggests that human epidermal growth factor receptor-2 (HER2), is overexpressed in around 20-30% of breast cancer cases, making it a highly promising TAA and an ideal target for therapeutic tumor vaccines (90, 91). Here, ERBB2 is linked to breast carcinoma.